Vaccination with leukemia-loaded dendritic cells eradicates residual disease and prevent relapse

Journal of Experimental Therapeutics and Oncology

Volumn 5, Issue 3, 2006, Pages 183-193

  Deeb, Dorrah ^a   Gao, Xiaohua ^a   Jiang, Hao ^b   Divine, George ^a   Dulchavsky, Scott A ^a   Gautam, Subhash C ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

Dendritic cells; Leukemia; Residual disease; TNF ; Vaccine

Indexed keywords

BCR ABL PROTEIN; CANCER VACCINE; CHROMIUM 51; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DNA; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; LEUKEMIA VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; IMMUNIZATION; LEUKEMIA; MALE; MINIMAL RESIDUAL DISEASE; MOUSE; MYELOID LEUKEMIA; NONHUMAN; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; SPLEEN CELL; TREATMENT OUTCOME; VACCINATION; ANIMAL; C3H MOUSE; CELLULAR IMMUNITY; IMMUNOLOGY; SECRETION;

ANIMALS; CANCER VACCINES; DENDRITIC CELLS; IMMUNITY, CELLULAR; INTERFERON TYPE II; LEUKEMIA; MALE; MICE; MICE, INBRED C3H; NEOPLASM, RESIDUAL; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646706342     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Champlin R. Separation of graft-versus-host disease and graft-versus-leukemia effect against chronic myelogenous leukemia. Exp Hemato 11:1148-11511, 1995.
2. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462-2465, 1990.
3. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271-296, 1991.
4. Banchcreau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392:245-252, 1998.
5. Austyn JM, Kupiec-Weglinski JW, Hankins DF, Morris PJ. Migration patterns of dendritic cells in the mouse. Homing to T cell-dependent areas of spleen, and binding within marginal zone. J Exp Med 167:646-651, 1988.
6. Austyn JM. Antigen uptake and presentation by dendritic-leukocytes. Seminar Immunol. 4:227-236, 1992.
7. Cella M, Sallusto F, and Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 9:10-16, 1997.
8. Roake JA, Rao AS, Morris PJ, Larsen CP, Hankins DF, Austyn JM. Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1. J Exp Med 181:2237-2247, 1995.
9. Cella M, Engering A, Pinet V, Lanzavecchia A. Inflammatory stimili induce accumulation of MHC class II complexes on dendritic cells. Nature 388:782-78, 1997.
10. Lutz MB, Girolomoni G, and Ricciardi-Castagnoli P. The role of cytokines in functional regulation and differentiation of dendritic cells. Immunobiol 195:431-455, 1995.
11. Inaba K, Witmer-Pack M, Inaba M, Hatchcock KS, Azuma M, Yagita H, et al. The tissue distribution of the B7-2 co-stimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J Exp Med 180:1849-1860, 1994.
12. Inaba K, Pack M, Inaba M, Sakuta H, Isdell F, Steinman RM. High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes. J Exp Med 186:665-672, 1997.
13. Macatonia SE, Hosken NA, Litton M, Litton M, Vieira P, Hsieh CS, et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naïve CD4+ T cells. J Immunol 154:5071-5079, 1995.
14. Heufler C, Koch F, Stanzl U, Topar G, Wysocka M, Trinchieri G, Enk A, Steinman RM, et al. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon- production by T helper 1 cells. Eur J Immunol 26: 659-668, 1996.
15. Celluzzi C, Mayordomo JI, Storkus WJ, Storkus WJ, Lotze MT, Falo LD Jr. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediatcd protective tumor immunity. J Exp Med 183:283-287, 1996.
16. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, et al. Bone-marrow derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat Med 1:1297-1302, 1995.
17. Paglia P, Chiodoni, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317-322, 1996.
18. Fields RC, Shimizu K, and Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 95:9482-9487, 1998.
19. Shimizu K, Thomas EK, Giedlin Met, Mule JJ. Enhancement of tumor lysate-and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res 61:2618-2624, 2001.
20. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52-58, 1995.
21. Nestle FO, Alijagie S, Gilliet M, Sun Y, Grabbe S, Dummer S, et al. Vaccination of myeloma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 3:328-332, 1998.
22. Chang AE, Redman BG, Whitfield JR, Nickoloff BJ, Braun TM, Lee et al. A phase I trial of tumor lysate-pulsed dendrityic cells in the treatment of advanced cancer. Clin Cancer Res 8:1021-1032, 2002.
23. Gautam SC, Pindolia KR, Xu YX, Janakiraman N, Chapman RA, Freytag SO. Antileukemic activity of TNF-α gene therapy with myeloid progenitor cells against minimal leukemia. J Hematother 7:115-125, 1998.
24. Gautam SC, Xu YX, Pindolia KR, Yegappan R, Janakiraman N, Chapman RA. TNF-" gene therapy with myeloid progenitor cells lacks the toxicities of systemic TNF-a therapy. J Hematother 8:237-245, 1999.
25. Xu YX, Deeb D, Gao X, Janakiraman N, Chapman RA, Gautam SC. In vitro analysis of the antileukemic effect of tumor necrosis factor-? gene therapy with myeloid progenitor cells: the role of dendritic cells. J Exp Therapeutics Oncol 3: 62-71, 2003.
26. Inaba K, Inaba M, Romani N, ava H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176:1693-1702, 1992.
27. Steinman RM, Pack M, and Inaba K. Dendritic cell development and maturation. Adv. Exp Med Biol 417:1-6, 1997.
28. Cella M, Salio M, Sakakibara Y, Langen H, Julkunen I, Lanzavecchia A. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med 189:821-829, 1999.
29. Chen B, Shi Y, Smith JD, Choi D, Geiger JD, Mule JJ. The role of tumor necrosis factor "in modulating the quantity of peripheral blood-derived, cytokine-driven human dendritic cells and its role in enhancing the quality of dendritic cell function in presenting soluble antigens to CD4+ T cells in vitro. Blood 91:4652-4661, 1998.
30. Josien R, Li HL, Ingulli E, Sarma S, Wong BR, Vologodskaia M, et al. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med 191:495-501, 2000.
31. Morel Y, Truneh A, Sweet RW, Olive D, Coslello RT. The TNF superfamily LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity. J Immunol 167:2479-2486, 2001.
32. Gautam SC, Xu YX, Dumaguin M, Janakiraman N, Chapman RA. Interleukin-12 (IL-12) gene therapy of leukemia: Immune and anti-leukemic effects of IL-12-transduced hematopoietic progenitor cells. Cancer Gene Ther 7:1060-1068, 2000.
33. Paczesny S, Beranger S, Salzmann JL, Klatzmann D, Colombo BM. Protection of mice against leukemia after vaccination with bone marrow-derived dendritic cells loaded with apoptotic leukemia cells. Cancer Res 61:2386-2389, 2001.
34. Shaif-Muthana M, McIntyre C, Sisley K, Rennie I, Murray A. Dead or alive: Immunogenicity of human melanoma cells when presented by dendritic cells. Cancer Res 60:6441-6447, 2000.
35. Kotera Y, Shimiuz K, Mule JJ. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res 61:8105-8109, 2001.
36. Brunner C, Seiderer J, Schlamp A, Bidlingmaier M, Eigler A, Haimerl W, et al. Enhanced dendritic cell maturation by TNF-a or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol 165:6278-6286, 2000.
37. Asavaroengchai W, Kotera Y, Mule JJ. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc. Natl. Acad. Sci 99:931-936, 2002.
38. Teshima T, Liu Chen, Lowler KP, Dranoff G, Ferrara JL. Donor leuekocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation. Cancer Res 62:796-800, 2002.